Preoperative GLP-1 receptor agonist use did not impact bariatric surgery outcomes, including weight loss at 1 year, diabetes control and postsurgical complications, according to a research letter published in JAMA Surgery.GLP-1s have become an integral part of obesity care, but clinicians still have questions about how pharmacologic therapy and surgical intervention interact.